Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Lexeo Therapeutics Inc (NASDAQ: LXEO) closed at $8.83 up 3.88% from its previous closing price of $8.5. In other words, the price has increased by $3.88 from its previous closing price. On the day, 0.8 million shares were traded. LXEO stock price reached its highest trading level at $8.94 during the session, while it also had its lowest trading level at $8.51.
Ratios:
For a deeper understanding of Lexeo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.43 and its Current Ratio is at 4.43. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on October 15, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On July 31, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $20.
On June 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $28.Robert W. Baird initiated its Outperform rating on June 13, 2024, with a $28 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 18 ’25 when Otero Jose Manuel sold 2,848 shares for $4.67 per share. The transaction valued at 13,294 led to the insider holds 60,372 shares of the business.
Robertson Jenny sold 542 shares of LXEO for $2,530 on Aug 18 ’25. The Chief Legal Officer now owns 62,556 shares after completing the transaction at $4.67 per share. On Aug 18 ’25, another insider, Adler Eric, who serves as the Chief Medical Officer of the company, sold 608 shares for $4.67 each. As a result, the insider received 2,838 and left with 67,073 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 476830720 and an Enterprise Value of 352816928.
Stock Price History:
The Beta on a monthly basis for LXEO is 1.33, which has changed by -0.06593406 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $11.72, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 54.37%, while the 200-Day Moving Average is calculated to be 99.81%.
Shares Statistics:
For the past three months, LXEO has traded an average of 702.31K shares per day and 1692150 over the past ten days. A total of 54.00M shares are outstanding, with a floating share count of 42.60M. Insiders hold about 21.12% of the company’s shares, while institutions hold 69.28% stake in the company. Shares short for LXEO as of 1759190400 were 5963424 with a Short Ratio of 8.49, compared to 1756425600 on 5230612. Therefore, it implies a Short% of Shares Outstanding of 5963424 and a Short% of Float of 12.100001.
Earnings Estimates
A detailed examination of Lexeo Therapeutics Inc (LXEO) is currently in progress, with 6.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.28 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.99 and -$3.03 for the fiscal current year, implying an average EPS of -$2.41. EPS for the following year is -$1.75, with 6.0 analysts recommending between -$1.12 and -$2.54.
